Application of allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome
10.3760/cma.j.cn115356-20210823-00190
- VernacularTitle:异基因造血干细胞移植在骨髓增生异常综合征中的应用
- Author:
Fang LI
1
;
Jianyong LI
;
Kourong MIAO
Author Information
1. 南京医科大学第一附属医院 江苏省人民医院血液科 210029
- Keywords:
Hematopoietic stem cell transplantation;
Myelodysplastic syndromes;
Transplantation conditioning;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2022;31(7):445-448
- CountryChina
- Language:Chinese
-
Abstract:
Myelodysplastic syndrome (MDS) is a kind of heterogeneous myeloid tumor that originates from hematopoietic stem cells and is characterized by hematopoietic dysfunction and high risk of transformation into myeloid leukemia. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has a great therapeutic potential for MDS patients and is the only effective option to cure MDS. Factors such as disease type, disease prognosis stratification, timing of transplantation, the intensity of preconditioning and relapse after transplantation all affect the survival of patients after transplantation. It is of great importance to clarify transplantation indications, flexibly choose patients at different times, select appropriate conditioning regimens and monitor the relapse after transplantation for improving the prognosis of MDS patients after transplantation. This article reviews the current progress of the application of allo-HSCT in MDS patients from these aspects.
